Bruce Booth

Bruce Booth is one of our founding investors and board members and has served on our Board of Directors since February 2016. Dr. Booth joined Atlas Venture in 2005 where he currently serves as partner. He is currently chairman of AVROBIO Inc., Kymera Therapeutics and Vigil Neuroscience, and he also serves on the board of several privately held companies. Dr. Booth previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures.

Dr. Booth serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, and Dana Farber’s Binney Street Capital advisory board. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer, and New England Disabled Sports, a charity dedicated to adaptive sports. Dr. Booth blogs about biotech and venture capital topics at, which is syndicated on Forbes. Prior to joining Atlas Venture, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University. Dr. Booth enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.